Interaction Study of the Combined Use of Paroxetine and Fosamprenavir-Ritonavir in Healthy Subjects
- 1 November 2007
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (11) , 4098-4104
Abstract
Human immunodeficiency virus-infected patients have an increased risk for depression. Despite the high potential for drug-drug interactions, limited data on the combined use of antidepressants and antiretrovirals are available. Theoretically, ritonavir-boosted protease inhibitors may inhibit CYP2D6-mediated metabolism of paroxetine. We wanted to determine the effect of fosamprenavir-ritonavir on paroxetine pharmacokinetics and vice versa and to evaluate the safety of the combination. Group A started with 20 mg paroxetine every day for 10 days; after a wash-out period of 16 days, subjects received paroxetine (20 mg every day) plus fosamprenavir-ritonavir (700/100 mg twice a day) from days 28 to 37. Group B received the regimens in reverse order. On days 10 and 37, pharmacokinetic curves were recorded. Twenty-six healthy subjects (18 females, 8 males) were included. Median (range) age and weight were 44.4 (18.2 to 64.3) years and 68.8 (51.0 to 89.4) kg. Three subjects were excluded (two because of adverse events; one for nonadherence). Addition of fosamprenavir-ritonavir to paroxetine resulted in a significant decrease in paroxetine exposure: the geometric mean ratios (90% confidence intervals) of paroxetine plus fosamprenavir-ritonavir to paroxetine alone were 0.45 (0.41 to 0.49) for the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ), 0.49 (0.45 to 0.53) for the maximum concentration of the drug in plasma ( C max ), and 0.75 (0.71 to 0.80) for the apparent elimination half-life ( t 1/2 ). The free fraction of paroxetine showed a median (interquartile range) increase of 30% (18 to 42%) after the addition of fosamprenavir-ritonavir. The AUC 0-12 , C max , C min , and t 1/2 of amprenavir and ritonavir were similar to those of historical controls. No serious adverse events occurred. Fosamprenavir-ritonavir reduced total paroxetine exposure by 55%. This is partly explained by protein displacement of paroxetine. We think that this interaction is clinically relevant and that titration to a higher dose of paroxetine may be necessary to accomplish the needed antidepressant effect.Keywords
This publication has 26 references indexed in Scilit:
- Amprenavir or Fosamprenavir plus Ritonavir in HIV InfectionDrugs, 2005
- Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy VolunteersJournal of Clinical Psychopharmacology, 2004
- FosamprenavirDrugs, 2004
- Cytochrome P450 Genotyping by Multiplexed Real-Time DNA Sequencing with Pyrosequencing™ TechnologyASSAY and Drug Development Technologies, 2002
- Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine PharmacokineticsThe Journal of Clinical Pharmacology, 2002
- Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjectsHuman Psychopharmacology: Clinical and Experimental, 2001
- In vivo modulation of CYP enzymes by quinidine and rifampinClinical Pharmacology & Therapeutics, 2000
- ParoxetineDrugs, 1991
- A review of the metabolism and pharmacokinetics of paroxetine in manActa Psychiatrica Scandinavica, 1989
- The influence of enzyme induction on polymorphic sparteine oxidation.British Journal of Clinical Pharmacology, 1986